在70岁及以上的社区老年人中,对数字跌倒预防干预措施安全步骤的成本效益分析
Saranda Bajraktari1, Marlene Sandlund1, Beatrice Pettersson1
1Department of Community Medicine and Rehabilitation, Physiotherapy, Umeå University, Umeå, Sweden.
European journal of ageing
|October 25, 2024
概括
安全步骤数字防摔计划是老年人节省成本的干预措施,降低了与落相关的成本,提高了生活质量. 即使使用保守估计,它也被证明是具有成本效益的.
科学领域:
- 老年学是一门学科.
- 公共卫生 公共卫生
- 卫生经济学 卫生经济学
背景情况:
- 跌倒是老年人受伤的主要原因,给个人和社会带来了巨大的成本.
- 全球人口老龄化预计将增加跌倒的发生率和相关的医疗保健支出.
- 确定具有成本效益,可扩展的防摔策略对于减轻这些负担至关重要.
研究的目的:
- 评估安全步骤数字防摔炼干预措施的12年成本效益.
- 评估不同的招聘成本和干预效果对成本效益的影响.
- 从社会角度分析干预,考虑质量调整寿命年 (QALYs) 和与落相关的成本.
主要方法:
- 在市政环境中进行的一项观察性研究,针对70岁及以上的社区居民.
- 用一个五态马尔科夫模型来模拟12年的成本和QALY.
- 干预效应基于元分析数据,将安全步骤与无干预组进行比较.
主要成果:
- 安全步骤的干预证明了成本效益,主导了无干预的替代方案.
- 增量成本效益比 (ICER) 为每获得的QALY7,616欧元,即使使用保守的效应估计.
- 这项干预措施被发现可以为有跌倒风险的老年人节省成本.
结论:
- 安全步骤数字干预是一种节省成本和潜在的成本效益的策略,用于预防老年人跌倒.
- 这些发现支持使用数字干预来降低老年人群中与跌倒相关的成本.
- 对数字防摔干预措施的有效性进行进一步的研究可以完善成本效益估计.
相关概念视频
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...